References used in the tables 1 Thiagarajan P, Wu KK. In vitro assays for evaluating platelet function. In: Gresele P, Page CP, Fuster V, Vermylen J, editors. Platelets in Thrombotic and Non-Thrombotic Disorders. Cambridge: Cambridge University Press; 2002: 459–70. 2 Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989;113:1219-1224 3 Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77:2547-2552. 4 Finazzi G, Budde U, Michiels JJ. Bleeding time and platelet function in essential thrombocythaemia and other myeloproliferative disorders. Leuk Lymphoma 1996; 22 suppl. 1:71-78. 5 De Paepe A, Malfait F. Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. Br J Haematol 2004; 127: 491-500. 6 Rand ML, Leung R, Packham MA. Platelet Function Assays. Transfus.Apher.Sci 2003;28:301-317. 7 Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1–20. 8 Shenkman B, Savion N, Dardik R, Tamarin I, Varon D. Testing of platelet deposition on polystyrene surface under flow conditions by cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2001;99:353–61. 9 Varon D, Savion N. Cone and plate(let) analyzer. In: Michelson A, editor. Platelets. San Diego: Academic Press 2002: 337–45. 10 Varon D, Lashevski I, Brenner B, Beyar R, Lanir N, Tamarin I, et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998;135:187–93. 11 Wang X, Dorsam RT, Lauver A, Wang H, Barbera FA, Gibbs S, Varon D, Savion N, Friedman SM, Feuerstein GZ. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion. J Pharmacol Exp Ther 2002;303:1114-20. 12 Cazenave JP, Packham MA, Mustard JF.Adherence of platelets to a collagen-coated surface: development of a quantitative method. J Lab Clin Med 1973 ;82:978-90. 13 Sun L, Feng S, Resendiz JC, Lu X, Durante W, Kroll MH.Role of the Pyk2-MAP kinase-cPLA2 signaling pathway in shear-dependent platelet aggregation. Ann Biomed Eng 2004 ;32:1193-201.. 14 Resendiz JC, Feng S, Ji G, Kroll MH. von Willebrand factor binding to platelet glycoprotein Ib-IX-V stimulates the assembly of an alpha-actinin-based signaling complex. J Thromb Haemost 2004 ;2:161-9.. 15 Resendiz JC, Feng S, Ji G, Francis KA, Berndt MC, Kroll MH.Purinergic P2Y12 receptor blockade inhibits shear- induced platelet phosphatidylinositol 3-kinase activation. Mol Pharmacol 2003 ;63:639-45. 16 Kroll MH, Feng S. Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal? Expert Rev Cardiovasc Ther 2005 ;3:941-51. 17 Varon D, Dardik R, Shenkman B, Kotev-Emeth S, Farzame N, Tamarin I, Savion N.A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997 ;85:283-94. 18 Kenet G, Lubetsky A, Shenkman B, Tamarin I, Dardik R, Rechavi G, Barzilai A, Martinowitz U, Savion N, Varon D. Cone and platelet analyzer (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998 ;101:255-9. 19 Levy Y, Shenkman B, Tamarin I, Pauzner R, Shoenfeld Y, Langevitz P, Savion N, Varon D.Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events. Arthritis Rheum 2005 ;52:4011-7. 20 Knobler H, Savion N, Shenkman B, Kotev-Emeth S, Varon D. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res 1998 ;90:181-90. 21 Kroll MH, Feng S. Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal? Expert Rev Cardiovasc Ther 2005 ;3:941-51. 22 Spectre G, Brill A, Gural A, Shenkman B, Touretsky N, Mosseri E, Savion N, Varon D. A new point-of-care method for monitoring anti-platelet therapy: application of the cone and plate(let) analyzer. Platelets 2005 ;16:293-9. 23 Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004 ;109:3171-5. 24 Feng S, Lu X, Kroll MH. Filamin A binding stabilizes nascent glycoprotein Ibalpha trafficking and thereby enhances its surface expression. J Biol Chem 2005 ;280:6709-15. 25 Shenkman B, Savion N, Dardik R, Tamarin I, Varon D.Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2000 ;99:353-61. 26 Shenkman B, Schneiderman J, Tamarin I, Kotev-Emeth S, Savion N, Varon D Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods. Thromb Res 2001 ;102:311-7. 27. Wang X, Dorsam RT, Lauver A, Wang H, Barbera FA, Gibbs S, Varon D, Savion N, Friedman SM, Feuerstein GZ.Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion. J Pharmacol Exp Ther 2002 ;303:1114-20. 28 Peerschke EI, Silver RT, Weksler B, Grigg SE, Savion N, Varon D. Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists. Br J Haematol 2004 ;127:195-203. 29 Chang HM and Robertson CR. Platelet aggregation by laminar shear and Brownian motion. Ann Biomed Eng 1976; 4: 151-83. 30 Frojmovic MM. Platelet aggregation in flow: Differential roles for adhesive receptors and ligands. Am Heart J Suppl 1998; 135: 5119-5131. 31 Xia Z, Frojmovic MM. Aggregation efficiency of activated normal or fixed platelets in a simple shear field: effect of shear and fibrinogen occupancy. Biophys J 1994; 66: 2110-201. 32 Frojmovic MM, Kasirer-Friede A, Goldsmith H. and Brown E. Surface-secreted von Willebrand Factor mediates aggregation of ADP-activated platelets at moderate shear stress: Facilitated by GPIb but controlled by GPIIb-IIIa. Thrombos Haemost 1997; 76: 568-576. 33 Bonnefoy A, Hantgan R, Legrand C, Frojmovic MM. A model of platelet aggregation involving multiple ineteractions of thrombospondin-1, fibrinogen and GPIIbIIIa receptor.J Bio. Chem 2001; 276: 5605-12. 34 Bonnefoy A, Liu Q, Jerome W Gray, Legrand C, and Frojmovic MM. Platelets in suspension require preactivation to adhere to immobilized fibrinogen. Annals New York Acad. Sci 2001; 936: 459-63. 35 Frojmovic MM, Nash G, and Diamond SL. Definitions in biorheology: cell aggregation and cell adhesion in flow. Recommendation of the Scientific Subcommittee on Biorheology of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2002;87:771. 36 Frojmovic M and Zolotarova E. Both shear and temperature can profoundly alter antithrombotic drug efficacy: demonstration with the P2Y12 ADP receptor antagonist, ARC-69931MX. J Thromb Haemost 2003 ; 1772. 37 Labarthe B, Frojmovic M and Legrand C. Inhibition and Reversal of Platelet Aggregation by αIIbβ3 Antagonists Depends on Flow Conditions:-Differential effects of Abciximab and Lamifiban. Br J Haematol 2005 ;131:348-55. 38 Falati S. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P- selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-98. 39 Ajzenberg N, Aubry P, Huisse M-G, Cachier A, ElAmara W, Feldman L, Himbert D, Baruch D, Guillin M-C, Steg G. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis. A case- control study. J American College Cardiology 2005; 45:1753. 40 Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001 ;98:3340-5. 41 Baumgartner HR, Haudenschild C. Adhesion of platelets to subendothelium. Ann NY Acad Sci 1972; 201: 22- 36. 42 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-79. 43 Baumgartner ER Effects of anticoagulation on the interaction of human platelets with subendothelium in flowing blood. Schweiz Med Wochenschr 1976; 106: 1367-8. 44 Sakariassen KS, Turitto VT, Baumgartner HR. Recollection on the development of flow devices for studying mechanisms of haemostasis and thrombosis in flowing whole blood. J Thromb Haemostas 2004; 2: 1681-90. 45 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to subendothelium. Nature 1979; 279: 636-8. 46 Sakariassen KS, Hanson SR, Cadroy Y. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb Res 2001; 104: 149-73. 47 Sakariassen KS, Turitto VT, Baumgartner HR. Recollection of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood. J Thromb Haemostas 2004; 2: 1681-90. 48 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-79. 49 Sakariassen KS, Aarts PAMM, de Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med 1983; 102: 522-35.